Using QDSA technology to assess cerebrovascular diseases

Research on the Application of Quantitative Digital Subtraction Angiography Hemodynamic Analysis Platform in Cerebrovascular Diseases

This study is trying to see if a new imaging technology can help doctors better understand and treat patients with cerebrovascular diseases by tracking their health over time.

Quick facts

• Study type: Observational
• Enrollment: 1000 (estimated)
• Ages: 1 Year to 80 Years
• Sex: All
• Sponsor: Beijing Tiantan Hospital (Academic / other)
• Locations: 1 site (Beijing, Beijing Municipality)
• Trial ID: NCT06902415 on ClinicalTrials.gov

What this trial studies

This observational study aims to create a prospective cohort of patients with cerebrovascular diseases, utilizing the Quantitative Digital Subtraction Angiography (QDSA) platform to analyze hemodynamic parameters. By integrating DSA features, clinical data, and follow-up information, the study seeks to validate the clinical utility of QDSA in preoperative evaluations and surgical planning. The research will track patient outcomes over time, focusing on the natural history of the disease, risk factors, and treatment efficacy, ultimately aiming to enhance clinical decision-making in cerebrovascular conditions.

Who should consider this trial

Good fit: Ideal candidates include patients diagnosed with various cerebrovascular diseases who have undergone DSA assessments.

Not a fit: Patients with cerebrovascular diseases not assessed using DSA or those with insufficient image quality for analysis may not benefit from this study.

Why it matters

Potential benefit: If successful, this study could improve diagnostic and therapeutic strategies for patients with cerebrovascular diseases.

How similar studies have performed: While the use of QDSA technology is relatively novel, similar studies in hemodynamic assessment have shown promising results.

Eligibility criteria

Inclusion Criteria:

1. Cerebrovascular diseases diagnosed and assessed by DSA for related risks and treatment options.
2. The DSA acquisition protocol complies with the standard procedure.
3. DSA images must include complete anteroposterior and lateral views.
4. Raw data must be available in DICOM format.
5. Image quality and pixel resolution must support data analysis.
6. Patients must undergo regular follow-ups.

Exclusion Criteria:

1. Cerebrovascular diseases not diagnosed or risk-assessed using DSA.
2. Patients with DSA image quality insufficient for image analysis and processing.
3. Severe organ diseases with an expected survival period of less than 2 years.
4. Inability to cooperate with treatment and follow-up.
5. Participation in other clinical trials within the past 6 months.
6. Other conditions deemed by the investigator as unsuitable for participation in this trial.

Where this trial is running

Beijing, Beijing Municipality

• Beijing Tiantan Hospital — Beijing, Beijing Municipality, China (Recruiting)

Study contacts

• Study coordinator: Yu Chen, MD

Conditions Cerebrovascular Disease; Quantitative Digital Subtraction Angiography; Hemodynamic; Stroke; Death; Outcome